Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
This Leading Pharma Company Has Grown Its Dividend 70% Since 2020
Investors on the hunt for a fast-growing dividends need look no further than Abbott Laboratories ABT -0.55% ▼ .
Claim 30% Off TipRanks Premium
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential
In December of last year, Abbott increased its dividend by 6.8% to $0.63 per share. It was the 54th year in a row that Abbott has increased its dividend. Since 2020, the dividend has grown by 70%, faster than just about any other dividend on offer.
Currently, ABT stock has a dividend yield of 2.42%, which is about double the average dividend yield among stocks listed in the benchmark S&P 500 index. Management at Abbott Labs continues to prioritize the dividend and rewarding its shareholders.
ABT Stock Performance
The rapid dividend growth at Abbott comes as the company’s stock has struggled. Over the last five years, the company’s share price has declined 15%. So far in 2026, the shares are down 16%. The main reason for the decline has been its baby-formula business.
Abbott has increasingly raised the price of its baby formula as manufacturing costs have risen and due to tariffs, hurting sales in the process. Most recently, Abbott reported that its nutrition sales were $1.9 billion, which was below analyst expectations. However, overall Abbott’s financial results have been strong and the company’s main business making medical devices remains solid.
While shareholders wait for ABT stock to recover, they can comfort themselves with the growing dividend.
Is ABT Stock a Buy?
Abbott Laboratories stock has a consensus Strong Buy rating among 15 analysts. That rating is based on 14 Buy and one Hold recommendations issued in the last three months. The average ABT price target of $137.14 implies 31% upside from current levels.
Disclaimer & DisclosureReport an Issue